Related Experiment Video

Updated: May 17, 2026

A Minimally Invasive Model of Aortic Stenosis in Swine
06:51

A Minimally Invasive Model of Aortic Stenosis in Swine

Published on: October 20, 2023

Copeptin constitutes a novel biomarker of degenerative aortic stenosis

Katarzyna Mizia-Stec1, Bartosz Lasota, Magdalena Mizia

  • 11st Department of Cardiology, Medical University of Silesia, 45/47 Ziołowa, 40-635, Katowice, Poland, kmizia@op.pl.

Heart and Vessels
|November 13, 2012
PubMed

Insights

Serum copeptin levels are elevated in patients with aortic stenosis (AS), correlating with disease severity. Copeptin shows diagnostic potential for AS, independent of coronary artery disease.

Area of Science:

  • Cardiology
  • Biomarker Research
  • Cardiovascular Diseases

Background:

  • Copeptin is an emerging biomarker for cardiovascular diseases.
  • The diagnostic utility of copeptin in degenerative aortic stenosis (AS) with preserved left ventricular systolic function remains unclear.
  • This study investigates copeptin's role in AS severity and its relationship with coronary artery disease (CAD).

Purpose of the Study:

  • To assess serum copeptin levels in patients with degenerative AS and preserved left ventricular systolic function.
  • To determine the association between copeptin levels and AS severity (effective orifice area).
  • To evaluate if coexisting coronary artery disease (CAD) influences copeptin levels.

Main Methods:

  • Sixty-four patients with AS (severe and moderate) and 23 controls were enrolled.
  • Serum copeptin and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were measured using enzyme-linked immunosorbent assay.
  • Correlation and receiver-operating characteristic (ROC) analyses were performed.

Main Results:

  • Mean serum copeptin concentrations were significantly higher in AS patients (severe: 405 pg/ml, moderate: 351 pg/ml) compared to controls (302 pg/ml).
  • Copeptin levels correlated inversely with effective orifice area (EOA) in AS patients (r = -0.55, P < 0.001).
  • Copeptin demonstrated good diagnostic performance for severe/moderate AS (sensitivity 71%, specificity 87%) with a cut-off of 354 pg/ml; no correlation with NT-proBNP or CAD was found.

Conclusions:

  • Serum copeptin is a novel biomarker for degenerative aortic stenosis.
  • Copeptin levels reflect AS severity in patients with preserved left ventricular systolic function.
  • Coexisting coronary artery disease does not interfere with copeptin's diagnostic value in AS.

More Related Videos

Measurement of Pulse Propagation Velocity, Distensibility and Strain in an Abdominal Aortic Aneurysm Mouse Model09:32

Measurement of Pulse Propagation Velocity, Distensibility and Strain in an Abdominal Aortic Aneurysm Mouse Model

Published on: February 23, 2020

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...